MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-13-2026
Edesa Biotech Operating Cycle 2011-2026 | EDSA
Annual Operating Cycle Edesa Biotech
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 97.1 | 193 | 255 | 48.6 | 105 | 318 | 55.5 | 119 | 21.6 | 20.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 318 | 20.4 | 123 |
Quarterly Operating Cycle Edesa Biotech
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 72.5 | 81.3 | 138 | 39.6 K | 39.6 K | 3.04 K | - | - | 450 | 301 | 3.07 K | 27.8 | 85.9 | 286 | 368 | 40.3 | 233 | 171 | 177 | 115 | 310 | 119 | 97.7 | 16.4 | 55.5 | 9.47 | 138 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 39.6 K | 9.47 | 3.41 K |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
INmune Bio
INMB
|
19.9 K | $ 1.53 | -0.65 % | $ 37.9 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.06 | -1.3 % | $ 3.66 B | USA |
 |
Exelixis
EXEL
|
140 | $ 48.46 | 9.1 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
325 | $ 2.56 | 3.86 % | $ 71.4 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.14 | 0.87 % | $ 653 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.04 | 2.65 % | $ 3.06 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 55.27 | 5.52 % | $ 4.97 B |  Schweiz |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.72 | 4.57 % | $ 458 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Завод ДИОД
DIOD
|
64.6 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
9.78 | - | - | - | Russia |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
Galapagos NV
GLPG
|
149 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |